These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33033903)

  • 1. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
    Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N
    AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
    Gill KL; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes.
    Docci L; Klammers F; Ekiciler A; Molitor B; Umehara K; Walter I; Krähenbühl S; Parrott N; Fowler S
    AAPS J; 2020 Oct; 22(6):131. PubMed ID: 33051808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes.
    Badée J; Qiu N; Collier AC; Takahashi RH; Forrest WF; Parrott N; Schmidt S; Fowler S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S42-S55. PubMed ID: 31502688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
    Cubitt HE; Houston JB; Galetin A
    Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates.
    Reddy MB; Bolger MB; Fraczkiewicz G; Del Frari L; Luo L; Lukacova V; Mitra A; Macwan JS; Mullin JM; Parrott N; Heikkinen AT
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
    Court MH; Duan SX; Guillemette C; Journault K; Krishnaswamy S; Von Moltke LL; Greenblatt DJ
    Drug Metab Dispos; 2002 Nov; 30(11):1257-65. PubMed ID: 12386133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs.
    Uchaipichat V; Suthisisang C; Miners JO
    Drug Metab Dispos; 2013 Jun; 41(6):1273-84. PubMed ID: 23554428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam.
    Ozbey AC; Keemink J; Wagner B; Pugliano A; Krähenbühl S; Annaert P; Fowler S; Parrott N; Umehara K
    Drug Metab Dispos; 2024 Jun; 52(7):614-625. PubMed ID: 38653501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
    Sun H; Zhang T; Wu Z; Wu B
    J Pharm Sci; 2015 Jan; 104(1):244-56. PubMed ID: 25393417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
    den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
    Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers.
    Furlan V; Demirdjian S; Bourdon O; Magdalou J; Taburet AM
    J Pharmacol Exp Ther; 1999 May; 289(2):1169-75. PubMed ID: 10215701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.
    Knights KM; Spencer SM; Fallon JK; Chau N; Smith PC; Miners JO
    Br J Clin Pharmacol; 2016 Jun; 81(6):1153-64. PubMed ID: 26808419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
    Court MH; Hao Q; Krishnaswamy S; Bekaii-Saab T; Al-Rohaimi A; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2004 Aug; 310(2):656-65. PubMed ID: 15044558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE).
    Gabor-Worwa E; Kowal-Chwast A; Gaud N; Gogola D; Littlewood P; Smoluch M; Brzózka K; Kus K
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):393-403. PubMed ID: 38642299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.
    Watanabe Y; Nakajima M; Yokoi T
    Drug Metab Dispos; 2002 Dec; 30(12):1462-9. PubMed ID: 12433820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
    Soars MG; Burchell B; Riley RJ
    J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.